Physician profile
Woon Ki Sim
NPI 1730130782
$4,903.78
in general payments reported to CMS, 2019-2025
33 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $1,064 · 2021: $1,050 · 2022: $665 · 2023: $579 · 2024: $634 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $900.50 | 2019-2023 | |
| Novo Nordisk INC | $667.77 | 2020-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $427.22 | 2022-2025 | |
| Amgen INC. | $366.18 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $351.21 | 2019-2025 | Farxiga |
| Glaxosmithkline, LLC. | $304.76 | 2019-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $302.91 | 2020-2025 | Mounjaro, Jardiance, Amyvid |
| Abbvie INC. | $238.52 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $213.21 | 2024-2025 | Rexulti |
| Allergan, INC. | $172.29 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $165.19 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.58 | 2020-2023 | Jardiance |
| Nestle Healthcare Nutrition INC. | $130.87 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $65.11 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $50.02 | 2023-2025 | Seglentis, Zoryve |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $46.63 | 2021-2024 | |
| Abbott Laboratories | $38.76 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.94 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $29.85 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $28.61 | 2025 | Zenpep |
| Arbor Pharmaceuticals, INC. | $28.34 | 2021 | |
| Irhythm Technologies, INC. | $19.91 | 2024 | Zio Xt Patch |
| Redhill Biopharma INC. | $18.35 | 2020 | |
| Seqirus USA INC | $18.03 | 2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $17.31 | 2020 | |
| Eisai INC. | $17.05 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.46 | 2024 | Edarbi |
| Ironwood Pharmaceuticals, INC | $15.18 | 2021 | |
| Pfizer INC. | $14.60 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.07 | 2021 | |
| Esperion Therapeutics, INC. | $13.76 | 2025 | Nexletol |
| Scilex Pharmaceuticals INC. | $13.42 | 2019 | |
| Medtronic, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Woon Sim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.